DK1167389T3 - Antistoffer mod SEMP1-proteinet, fremgangsmåde til fremstilling heraf samt anvendelse deraf - Google Patents

Antistoffer mod SEMP1-proteinet, fremgangsmåde til fremstilling heraf samt anvendelse deraf

Info

Publication number
DK1167389T3
DK1167389T3 DK01114743T DK01114743T DK1167389T3 DK 1167389 T3 DK1167389 T3 DK 1167389T3 DK 01114743 T DK01114743 T DK 01114743T DK 01114743 T DK01114743 T DK 01114743T DK 1167389 T3 DK1167389 T3 DK 1167389T3
Authority
DK
Denmark
Prior art keywords
semp1
dsm
antibodies
protein
preparation
Prior art date
Application number
DK01114743T
Other languages
Danish (da)
English (en)
Inventor
Thorsten Hoevel
Stefan Koch
Manfred Kubbies
Olaf Mundigl
Petra Rueger
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26071070&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1167389(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP00113344A external-priority patent/EP1167387A1/en
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of DK1167389T3 publication Critical patent/DK1167389T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK01114743T 2000-06-23 2001-06-22 Antistoffer mod SEMP1-proteinet, fremgangsmåde til fremstilling heraf samt anvendelse deraf DK1167389T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00113344A EP1167387A1 (en) 2000-06-23 2000-06-23 Antibodies against SEMP1, methods for their production and uses thereof
EP01107799 2001-04-05

Publications (1)

Publication Number Publication Date
DK1167389T3 true DK1167389T3 (da) 2007-11-12

Family

ID=26071070

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01114743T DK1167389T3 (da) 2000-06-23 2001-06-22 Antistoffer mod SEMP1-proteinet, fremgangsmåde til fremstilling heraf samt anvendelse deraf

Country Status (10)

Country Link
US (1) US6627439B2 (ja)
EP (1) EP1167389B1 (ja)
JP (1) JP3542784B2 (ja)
AT (1) ATE366746T1 (ja)
AU (1) AU750296B2 (ja)
CA (1) CA2348026C (ja)
DE (1) DE60129278T2 (ja)
DK (1) DK1167389T3 (ja)
ES (1) ES2290072T3 (ja)
PT (1) PT1167389E (ja)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
EP2311979A1 (en) * 2002-08-20 2011-04-20 Millennium Pharmaceuticals, Inc. Compositions, kits and methods for identification, assessment, prevention and therapy of cervical cancer
CA2649962A1 (en) * 2006-05-04 2007-11-15 The Rockefeller University Hcv coreceptor and methods of use thereof
US8518408B2 (en) * 2008-09-25 2013-08-27 Inserm (Institut National De La Sante Et De La Recherche Medicale) Monoclonal anti-claudin 1 antibodies for the inhibition of hepatitis C virus infection
CA2800734A1 (en) 2010-05-25 2011-12-01 Universite De Strasbourg Combination of anti-envelope antibodies and anti-receptor antibodies for the treatment and prevention of hcv infection
WO2013024155A1 (en) 2011-08-17 2013-02-21 Inserm (Institut National De La Sante Et De La Recherche Medicale) Combinations of anti-hcv-entry factor antibodies and direct acting antivirals for the treatment and the prevention of hcv infection
WO2013024156A2 (en) 2011-08-17 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinations of anti-hcv-entry factor antibodies and interferons for the treatment and the prevention of hcv infection
WO2013024157A2 (en) 2011-08-17 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinations of host targeting agents for the treatment and the prevention of hcv infection
JP6393875B2 (ja) * 2013-02-28 2018-09-26 公益財団法人ヒューマンサイエンス振興財団 抗体
WO2015014659A1 (en) * 2013-08-02 2015-02-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-claudin 1 antibodies and uses thereof
JP2016525558A (ja) 2013-08-02 2016-08-25 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 結腸直腸ガンの処置に使用するための抗クローディン１抗体
EP3070103A1 (en) 2015-03-19 2016-09-21 Institut Hospitalier Universitaire De Strasbourg Anti-Claudin 1 monoclonal antibodies for the prevention and treatment of hepatocellular carcinoma
EP3821946A1 (en) 2019-11-12 2021-05-19 Université de Strasbourg Anti-claudin-1 monoclonal antibodies for the prevention and treatment of fibrotic diseases
CN113455494A (zh) * 2021-05-12 2021-10-01 南京生航生物技术有限公司 一种无血清细胞冻存液及制备方法和制备装置
WO2023170606A1 (en) 2022-03-08 2023-09-14 Alentis Therapeutics Ag Use of anti-claudin-1 antibodies to increase t cell availability
WO2023233364A1 (en) 2022-06-01 2023-12-07 Alentis Therapeutics Ag Use of anti-claudin-1 antibodies to treat cholangiocarcinoma
WO2023233363A1 (en) 2022-06-01 2023-12-07 Alentis Therapeutics Ag Use of anti-claudin-1 antibodies to treat cholangiopathies
WO2024069009A1 (en) 2022-09-30 2024-04-04 Alentis Therapeutics Ag Treatment of drug-resistant hepatocellular carcinoma

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8901198A (en) 1997-08-06 1999-03-01 Millennium Pharmaceuticals, Inc. Tango-71, tango-73, tango-74, tango-76, and tango-83 nucleic acid molecules and polypeptides
CN1270637A (zh) 1997-08-08 2000-10-18 华盛顿大学 新的衰老因子基因p23的分离
WO2000000609A2 (en) 1998-06-29 2000-01-06 Incyte Pharmaceuticals, Inc. Molecules associated with apoptosis

Also Published As

Publication number Publication date
PT1167389E (pt) 2007-09-27
DE60129278D1 (de) 2007-08-23
JP2002332300A (ja) 2002-11-22
US6627439B2 (en) 2003-09-30
AU750296B2 (en) 2002-07-11
ATE366746T1 (de) 2007-08-15
AU5007901A (en) 2002-01-03
DE60129278T2 (de) 2008-03-20
CA2348026C (en) 2005-06-07
US20020150574A1 (en) 2002-10-17
EP1167389B1 (en) 2007-07-11
EP1167389A1 (en) 2002-01-02
ES2290072T3 (es) 2008-02-16
JP3542784B2 (ja) 2004-07-14
CA2348026A1 (en) 2001-12-23

Similar Documents

Publication Publication Date Title
DK1167389T3 (da) Antistoffer mod SEMP1-proteinet, fremgangsmåde til fremstilling heraf samt anvendelse deraf
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
EP1378525A3 (en) Humanized antibodies that bind to the antigen bound by antibody NR-LU-13 and their use in pretargeting methods
GB2383331A (en) Monoclonal antibody DS6 Tumor-associated antigen CA6 and methods of use thereof
DK1565489T3 (da) Internaliserende antistoffer specifikke for RAAG10-celleoverflademålet
ATE384792T1 (de) Antikörpervarianten mit höheren bindungsaffinitäten im vergleich zu parentalen antikörpern
CY1109645T1 (el) Ανθρωπινος πρωτεϊνικος υποδοχεας τυπου toll, σχετικα αντιδραστηρια και μεθοδοι
CY1108545T1 (el) Πρωτεϊνες υπομοναδας υποδοχεα κυτοκινης θηλαστικου, σχετικα αντιδραστηρια και μεθοδοι
HK1038069A1 (en) Immunoassay for c.reactive protein
NO20023788L (no) Antistoff som binder humant interleukin-18 samt fremgangsmater ved fremstilling og anvendelse derav
DK1308507T3 (da) Monoklonalt antistof mod HCV-kerneantigen
WO2004022717A3 (en) Minimally immunogenic variants of humanized col-1 antibody against carcinoembryonic antigen
NZ230148A (en) Ibd (infectious bursal disease) monoclonal antibody vaccines, immunised chicks and a method of assaying for ibd
EP1433792A8 (en) Human receptor proteins, related reagents and methods
GB2278357B (en) Humanised antibodies directed against A33 antigen
NZ305083A (en) Use of cd40 binding proteins (a cd40 ligand or monoclonal antibody that specifically binds to cd40) for stimulating a immune response
EP1354896A4 (en) NEW MONOCLONAL ANTIBODY
WO2002076406A3 (en) Antibodies against autoantigens of primary biliary cirrhosis and methods of making and using them
EP1401470A4 (en) NEW ANTIBODIES BINDING TO ANTIGENIC POLYPEPTIDES, THE ANTIGENE ENCODING NUCLEIC ACIDS AND METHOD FOR THEIR USE
DK0889907T3 (da) Monoklonale antistoffer, som binder humant væksthormon (hGH)
ZA200200730B (en) Human monoclonal antibodies to prostate specific membrane antigen.
AU2002325647A1 (en) Monoclonal antibody cb874 directed to an unknown antigen from umbilical cord blood
BR0204612A (pt) Anticorpos monoclonais antinúcleo de hcv
EP1621209A3 (en) Vaccines based on domains of chimeric immunoglobulin E peptides